What insurance policy changes affect CPT 45399?

There are 5 tracked policy changes affecting CPT 45399, including updates from Independence Blue Cross. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 45399?

Payers that have issued tracked updates for CPT 45399 include: Independence Blue Cross.

How do I get notified when CPT 45399 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 45399. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 45399?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

45399 Insurance Policy Changes

CPT 45399 is referenced in 5 tracked payer policy changes from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 45399 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact
11.03.18, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross has reissued policy 11.03.18 to establish coverage criteria for Endoscopic Submucosal Dissection (ESD) across four clinical scenarios: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy defines specific lesion characteristics, invasion depth thresholds, and lymph node metastasis documentation requirements that must be met for coverage. Billing teams must now ensure claims include proper documentation of lesion staging and use appropriate HCPCS code C9779 for covered procedures.
High impact
MA00.005aq, Experimental/Investigational Services
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross Medicare Advantage policy MA00.005at (effective 10/01/2025) designates 11 new CPT codes, 4 new HCPCS codes, and 4 unlisted code services as experimental/investigational and therefore non-covered. Simultaneously, 3 CPT codes (43497, 0338T, 0339T) and 2 additional CPT codes (0569T, 0570T) are removed from the experimental list because they are now considered medically necessary or addressed in other policies. Billing teams must immediately identify claims using these codes and implement denial management strategies.
Medium impact
MA11.118, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross has reissued MA11.118 to communicate coverage criteria for Endoscopic Submucosal Dissection (ESD) procedures across four indication categories: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy establishes specific medical necessity criteria for each indication, including lesion size, differentiation, invasion depth, and lymph node metastasis risk documentation. Billing teams must recognize the HCPCS code C9779 for ESD procedures and CPT unlisted codes (43499, 43999, 45399, 45999) as applicable billing options.
Medium impact
MA11.118, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross reissued MA11.118 effective 10/01/2025, establishing coverage criteria for Endoscopic Submucosal Dissection (ESD) across four clinical scenarios: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy specifies detailed lesion characteristics and diagnostic requirements that must be met for coverage; claims not meeting all criteria will be denied.
Medium impact
11.03.18, Endoscopic Submucosal Dissection (ESD)
Independence Blue Cross·Effective Oct 1, 2025
Independence Blue Cross reissued Policy 11.03.18 to communicate coverage criteria for Endoscopic Submucosal Dissection (ESD) across four indications: esophageal squamous cell carcinoma/dysplasia, early-stage esophageal adenocarcinoma/Barrett esophagus dysplasia, gastric early adenocarcinoma, and colorectal lesions. The policy establishes specific clinical criteria (lesion size, differentiation, invasion depth, metastasis risk) that must be met for coverage, and designates all other ESD uses as experimental/investigational and not covered.

All billing codes J3590 C9399 J3490 99213 99214 99212

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

11.03.18, Endoscopic Submucosal Dissection (ESD)

MA00.005aq, Experimental/Investigational Services

MA11.118, Endoscopic Submucosal Dissection (ESD)

MA11.118, Endoscopic Submucosal Dissection (ESD)

11.03.18, Endoscopic Submucosal Dissection (ESD)